Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Candel Therapeutics, Inc.
Candel Therapeutics, Inc. News
Nov 13, 2025 - proactiveinvestors.com
Candel Therapeutics highlights third quarter milestones across cancer immunotherapy pipeline
Nov 13, 2025 - globenewswire.com
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Nov 4, 2025 - proactiveinvestors.com
Candel Therapeutics to highlight immunotherapy advances at SITC 2025
Nov 4, 2025 - globenewswire.com
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
Candel Therapeutics, Inc. Quantitative Score
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Candel Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Candel Therapeutics, Inc. Financials
Table Compare
Compare CADL metrics with: | |||
|---|---|---|---|
Earnings & Growth | CADL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CADL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CADL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CADL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Candel Therapeutics, Inc. Income
Candel Therapeutics, Inc. Balance Sheet
Candel Therapeutics, Inc. Cash Flow
Candel Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Candel Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, Chief Executive Officer & Director |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
| Ms. Ileen B. Winick | Chief People Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, Chief Executive Officer & Director | 1961 | 1.45M | |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer | 1978 | 726.22K | |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer | 1968 | 613.23K | |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | Female | 1961 | -- |
| Ms. Ileen B. Winick | Chief People Officer | Female | -- |
Candel Therapeutics, Inc. Insider Trades
| Date | 28 Jul |
| Name | Nichols William Garrett |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 937 |
| Date | 28 Jul |
| Name | Nichols William Garrett |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 937 |
| Date | 28 Jul |
| Name | Nichols William Garrett |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 937 |
| Date | 30 Jun |
| Name | Nichols William Garrett |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 781 |
| Date | 30 Jun |
| Name | Nichols William Garrett |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 781 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 28 Jul | Nichols William Garrett | Chief Medical Officer | Acquired | M-Exempt | 937 |
| 28 Jul | Nichols William Garrett | Chief Medical Officer | Disposed | S-Sale | 937 |
| 28 Jul | Nichols William Garrett | Chief Medical Officer | Disposed | M-Exempt | 937 |
| 30 Jun | Nichols William Garrett | Chief Medical Officer | Acquired | M-Exempt | 781 |
| 30 Jun | Nichols William Garrett | Chief Medical Officer | Disposed | S-Sale | 781 |